Status:
UNKNOWN
Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia
Lead Sponsor:
Peking University People's Hospital
Conditions:
Acute Leukemia
Eligibility:
All Genders
2-60 years
Brief Summary
Allogeneic stem cell transplantation (Allo-HSCT) is the effective and even the only treatment for hematological malignancies. The "GIAC" protocol established by our center has successfully crossed the...
Detailed Description
Allogeneic stem cell transplantation (Allo-HSCT) is the effective and even the only treatment for hematological malignancies. The "GIAC" protocol established by our center has successfully crossed the...
Eligibility Criteria
Inclusion
- 2-60 years old, all genders;
- the first complete remission phase (CR1) of acute leukemia;
- planning to receive haplotype PBSCT;
- no uncontrolled current infections (new infections, body temperature still above 38 ℃ after treatment with broad-spectrum antibiotics for 72h, except for other non-infectious factors);
- no organ failure.
Exclusion
- with poor compliance;
- with uncontrolled current infections；
- pregnancy;
- donors with contraindications of mobilization and collection of peripheral blood stem cells;
- with mental sickness
Key Trial Info
Start Date :
November 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2025
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT03756675
Start Date
November 1 2018
End Date
November 1 2025
Last Update
September 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044